Antibiotice Ia (ATB) - Total Liabilities
Based on the latest financial reports, Antibiotice Ia (ATB) has total liabilities worth RON460.49 Million RON (≈ $105.73 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Antibiotice Ia to assess how effectively this company generates cash.
Antibiotice Ia - Total Liabilities Trend (2020–2025)
This chart illustrates how Antibiotice Ia's total liabilities have evolved over time, based on quarterly financial data. See ATB book value for net asset value and shareholders' equity analysis.
Antibiotice Ia Competitors by Total Liabilities
The table below lists competitors of Antibiotice Ia ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
Turkey | TL5.49 Billion |
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
USA | $12.12 Million |
|
Esso (Thailand) Public Company Limited
BK:BSRC
|
Thailand | ฿36.69 Billion |
|
Sanghvi Movers Limited
NSE:SANGHVIMOV
|
India | Rs7.31 Billion |
|
Lowland Investment Co
LSE:LWI
|
UK | £51.86 Million |
|
CARYSIL LIMITED
NSE:CARYSIL
|
India | Rs4.74 Billion |
|
Baader Bank Aktiengesellschaft
F:BWB
|
Germany | €4.09 Billion |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
USA | $945.65 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Antibiotice Ia's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Antibiotice Ia stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Antibiotice Ia's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Antibiotice Ia (2020–2025)
The table below shows the annual total liabilities of Antibiotice Ia from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | RON460.49 Million ≈ $105.73 Million |
+19.62% |
| 2024-09-30 | RON384.95 Million ≈ $88.39 Million |
+31.74% |
| 2023-09-30 | RON292.21 Million ≈ $67.10 Million |
+35.88% |
| 2022-09-30 | RON215.04 Million ≈ $49.38 Million |
-25.95% |
| 2021-09-30 | RON290.40 Million ≈ $66.68 Million |
+1.63% |
| 2020-09-30 | RON285.73 Million ≈ $65.61 Million |
-- |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more